The ANDROMEDA prospective cohort study: Predictive value of combined criteria to tailor breast cancer screening and new opportunities from circulating markers: Study protocol

Livia Giordano, Federica Gallo, Elisabetta Petracci, Giovanna Chiorino, Nereo Segnan, C. Anatrone, F. Artuso, M. Beraudi, D. Casella, M. Ceresa, F. Di Stefano, M. Dotti, S. Feira, A. Frigerio, F. Garena, P. Giubilato, M. P. Mano, V. Marra, A. Menardi, A. OrtaleS. Pelosin, A. Pezzana, S. Pitarella, A. Ponti, F. Saba, V. Vergini, P. Vicari, S. Ayoubi, S. Debianchi, E. Favettini, I. Gregnanin, L. Iacazio, M. Mello-Grand, P. Ostano, P. Presti, Andromeda working group

Research output: Contribution to journalArticlepeer-review


Background: In recent years growing interest has been posed on alternative ways to screen women for breast cancer involving different imaging techniques or adjusting screening interval by breast cancer risk estimates. A new research area is studying circulating microRNAs as molecular biomarkers potentially useful for non invasive early detection together with the analysis of single-nucleotide polymorphisms (SNPs). The Andromeda study is a prospective cohort study on women attending breast cancer screening in a northern Italian area. The aims of the study are: 1) to define appropriate women risk-based stratifications for personalized screening considering different factors (reproductive, family and biopsy history, breast density, lifestyle habits); 2) to evaluate the diagnostic accuracy of selected circulating microRNAs in a case-control study nested within the above mentioned cohort. Methods: About 21,000 women aged 46-67 years compliant to screening mammography are expected to be enrolled. At enrolment, information on well-known breast cancer risk factors and life-styles habits are collected through self-admistered questionnaires. Information on breast density and anthropometric measurements (height, weight, body composition, and waist circumference) are recorded. In addition, women are requested to provide a blood sample for serum, plasma and buffy-coat storing for subsequent molecular analyses within the nested case-control study. This investigation will be performed on approximately 233 cases (screen-detected) and 699 matched controls to evaluate SNPs and circulating microRNAs. The whole study will last three years and the cohort will be followed up for ten years to observe the onset of new breast cancer cases. Discussion: Nowadays women undergo the same screening protocol, independently of their breast density and their individual risk to develop breast cancer. New criteria to better stratify women in risk groups could enable the screening strategies to target high-risk women while reducing interventions in those at low-risk. In this frame the present study will contribute in identifying the feasibility and impact of implementing personalized breast cancer screening. Trial registration:NCT02618538(retrospectively registered on 27-11-2015).

Original languageEnglish
Article number785
JournalBMC Cancer
Issue number1
Publication statusPublished - Nov 22 2017


  • Breast cancer
  • Risk prediction models
  • Tailored screening

ASJC Scopus subject areas

  • Oncology
  • Genetics
  • Cancer Research


Dive into the research topics of 'The ANDROMEDA prospective cohort study: Predictive value of combined criteria to tailor breast cancer screening and new opportunities from circulating markers: Study protocol'. Together they form a unique fingerprint.

Cite this